{"id":"fuzheng-huayu-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Mild hepatic enzyme elevation"}]},"_chembl":{"chemblId":"CHEMBL635","moleculeType":"Small molecule","molecularWeight":"358.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The tablet combines multiple herbal components designed to reduce hepatic inflammation, inhibit hepatic stellate cell activation, and promote apoptosis of activated fibroblasts. It works to improve microcirculation and enhance hepatocyte regeneration, thereby reversing established liver fibrosis and improving overall liver function in chronic liver disease.","oneSentence":"Fuzheng Huayu tablet is a traditional Chinese medicine formulation that promotes liver fibrosis reversal and hepatic function recovery through anti-inflammatory and antifibrotic pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:46:54.341Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatic fibrosis and cirrhosis"},{"name":"Chronic hepatitis B with fibrosis"},{"name":"Chronic liver disease with fibrotic progression"}]},"trialDetails":[{"nctId":"NCT07017426","phase":"NA","title":"Fuzheng Huayu Tablets Reduce the Occurrence of Re-Decompensation Events in Patients With First Decompensation of Hepatitis B-Related Liver Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study","status":"NOT_YET_RECRUITING","sponsor":"Zhiyun Yang","startDate":"2025-07-01","conditions":"Decompensated Hepatitis B Cirrhosis","enrollment":432},{"nctId":"NCT04279197","phase":"PHASE2","title":"Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu","status":"COMPLETED","sponsor":"ShuGuang Hospital","startDate":"2020-04-23","conditions":"Pulmonary Fibrosis Due to COVID-19","enrollment":142},{"nctId":"NCT00854087","phase":"PHASE2","title":"Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis","status":"COMPLETED","sponsor":"Tarek Hassanein","startDate":"2010-08","conditions":"Chronic Hepatitis C Infection","enrollment":118},{"nctId":"NCT04645407","phase":"PHASE4","title":"Effects of Fuzheng Huayu Tablets on COVID-19","status":"COMPLETED","sponsor":"ShuGuang Hospital","startDate":"2020-02-01","conditions":"Novel Coronavirus Pneumonia","enrollment":66},{"nctId":"NCT02945956","phase":"PHASE4","title":"Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2018-04-05","conditions":"Portal Hypertension","enrollment":192},{"nctId":"NCT02945982","phase":"PHASE4","title":"Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Fuzheng Huayu and Entecavir","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2018-04-05","conditions":"Portal Hypertension","enrollment":184},{"nctId":"NCT02241590","phase":"PHASE4","title":"Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2014-09","conditions":"Liver Cirrhosis Due to Hepatitis B Virus","enrollment":700},{"nctId":"NCT02241616","phase":"PHASE4","title":"Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2014-09","conditions":"Hepatitis B Virus Related Cirrhosis","enrollment":350},{"nctId":"NCT00543426","phase":"PHASE4","title":"Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2007-09","conditions":"Posthepatitic Cirrhosis","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FZHY","Gan Ping","319 Recipe"],"phase":"marketed","status":"active","brandName":"Fuzheng Huayu tablet","genericName":"Fuzheng Huayu tablet","companyName":"ShuGuang Hospital","companyId":"shuguang-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fuzheng Huayu tablet is a traditional Chinese medicine formulation that promotes liver fibrosis reversal and hepatic function recovery through anti-inflammatory and antifibrotic pathways. Used for Hepatic fibrosis and cirrhosis, Chronic hepatitis B with fibrosis, Chronic liver disease with fibrotic progression.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}